| JOURNAL HOME | CME HOME | THIS MONTH | PAST ISSUES | ETOC | COLLECTIONS |
| AUTHORS | REVIEWERS | EDITORIAL BOARD | FEEDBACK | RSS | HELP |
| ||||||||||||||
| ||||||||||||||
|
|
|
|
||||||||||||
|
||||||||||||||
Department of Surgical, Anesthesiological and Radiological Science, Section of Anesthesia and Intensive Care, S. Anna Hospital, University of Ferrara, Ferrara, Italy
Address correspondence and reprint requests to Carlo Alberto Volta, MD, Department of Surgical, Anesthesiological and Radiological Science, Section of Anesthesia and Intensive Care, S. Anna Hospital, University of Ferrara, Corso Giovecca 203, 44100 Ferrara, Italy. Address e-mail to vlc{at}dns.unife.it.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Thoracic surgery is made possible by the use of a double-lumen endobronchial tube (DLTs), the diameter of which is much larger than that of a normal single-lumen endotracheal tube; DLTs probably cause more trauma (5). However, despite their larger external diameter, the resistance of flow (V') of DLTs is increased because they are essentially two small-diameter tubes in parallel. Moreover, patients undergoing thoracic surgery frequently exhibit chronic airflow obstruction due to a smoking history, which has been shown to increase the rate of bronchospasm (6). Although bronchodilating drugs are often inhaled in mechanically-ventilated patients with COPD, the improvement in respiratory resistance is, in general, extremely variable (7–10). This may be because permanent structural features lead to a net decrease in bronchial diameter or because patients with COPD exhibit small-airway closure and gas trapping (11).
Hence, we hypothesized that patients with COPD undergoing thoracic surgery cannot respond to volatile anesthetics and theoretically have an increased risk of bronchospasm and pulmonary complication due to pulmonary hyperinflation than patients with normal respiratory function. The aim of this study was to verify the bronchodilating effect of different volatile anesthetics in patients with COPD undergoing thoracic surgery.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
|
|
Immediately after tracheal intubation, ventilation was controlled (Servo 900B; Siemens, Elema) at 12 breaths/min, with a tidal volume (Vt) of approximately 8 mL/kg, a constant inspiratory V' rate of 0.5 L/s, and an inspiratory time percentage of 25%, with an end-inspiratory pause of 10%. The ventilator was set to deliver a Vt with a square-wave V'-time profile. This setting remained constant throughout the study. Extrinsic positive end-expiratory pressure was set to 0.
V' was measured with a heated pneumotachograph connected to a differential pressure transducer. The response of the pneumotachograph was linear over the experimental range of V'. Vt was calculated by integration of the V' signal. Pressure at the airway opening was measured through a side port on the connector between the respiratory circuit and the endotracheal tube by using a differential pressure transducer. The transducer was calibrated before and after each study. Special care was taken to avoid gas leakage in the equipment and around the tracheal and bronchial cuffs.
The V' and pressure signals were amplified, low-pass-filtered at 50 Hz, and digitized at 100 Hz by a 16-bit analog-to-digital converter. The digitized data were stored on computer hard disk for subsequent analysis. Data was analyzed with the Anadat data-analysis software (Version 5.1; RMT-InfoDat Inc., Montreal, Quebec, Canada).
Respiratory mechanics were assessed by the constant V'/rapid occlusion method previously described in detail (14). The end-inspiratory occlusion, obtained by increasing the end-inspiratory pause on the ventilator to 30%, lasted a mean of 1.5 s. This allowed measurement of the inspiratory resistance of the respiratory system. After end-inspiratory airway occlusion, the pressure at the airway opening exhibited an initial rapid decrease from the maximum pressure (Pmax) to the pressure registered at the point of zero V' (P1). During this period, the contribution of reduction in pressure due to volume loss by continuing gas exchange is generally considered negligible. By dividing airway opening Pmax – P1 by the V' immediately preceding the occlusion, the V' resistance of the endotracheal tube plus that of the total respiratory system (Rtot,rs) was obtained. By subtracting the V' resistance of the endotracheal tube, the minimal (Rmin,rs) inspiratory resistances of the respiratory system (upper airways not included) were obtained. In general, the V' resistance of the endotracheal tube is curvilinear and depends on the size of the tubes used. In the case of endotracheal tubes for thoracic surgery, there are two lumens to be considered in computation of resistance. Hence it is necessary to measure the pressure/V' relationships of both lumens, and this is best described by Rohrer’s equation:
|
|
where P represents the pressure decrease across each tube and K1 and K2 are constants related, respectively, to the laminar and turbulent V' (15). Both constants were determined for the gas mixture normally used during anesthesia (oxygen 40% in air). These measurements were taken with the V' of the gas mixture injected in the experimental inspiratory direction. The total resistance of the DLT (tracheal and bronchial lumen) was calculated accordng to
|
|
(16) and then subtracted from the calculated value of Rtot,rs. Finally, dynamic positive end expiratory pressure was calculated as the value of airway pressure registered at zero 
'.
Measurements of Rmin,rs began within 2 min after tracheal intubation, as soon as mechanical ventilation was established according to existing guidelines. On completion of the measurements (<30 s), patients were randomized by using sequentially numbered, opaque, sealed envelopes to one of three anesthetic maintenance options: 1) thiopental infusion at 0.30 mg · kg–1 · min–1, 2) 2.3% sevoflurane in oxygen, or 3) 1.4% isoflurane in oxygen. Volatile anesthetic concentrations were chosen to approximate 1.1 minimum alveolar anesthetic concentration (MAC). Overpressure was used to achieve the desired end-tidal concentration as rapidly as possible. Thereafter, the fresh gas concentration was adjusted as necessary to maintain a constant end-tidal concentration throughout the study (1). Rmin,rs was measured 5 and 10 min after maintenance anesthesia was initiated. It should be noted that the correct position of the endotracheal tube was always verified by direct bronchoscopy after completion of the protocol. If an incorrect tube position was detected, the patient was removed from the study and the data were discarded. After completion of the protocol, anesthesia was continued by using volatile anesthetics (either sevoflurane or isoflurane) and appropriate doses of fentanyl and vecuronium.
The electrocardiogram, heart rate, systemic arterial blood pressure, pulsatile oxygen saturation, end-tidal carbon dioxide, and inhaled anesthetic end-tidal concentrations were continuously monitored. Boluses of 1 to 2 mg of etilefrine were administered IV by the treating physician in case of hypotension (mean arterial blood pressure decrease >25% from preinduction baseline).
Results are expressed as means ± sd. The Kolmogorov-Smirnov one-sample test was used to verify the normal distribution. Comparisons for continuous variables within and between groups were performed with the Friedman repeated-measures analysis of variance on ranks. To isolate divergent variables, pairwise multiple comparison procedures (Dunnett’s method) were used. Measurements of Rmin,rs at 5 and 10 min were analyzed as the percentage change from the thiopental baseline before initiation of gas or infusion. Categorical variables were compared by using the 
2 statistic. P < 0.05 was considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The control group (42 patients) and the patients with COPD were similar in terms of sex, age, height, percentage of smokers, and smoking history. They differed mainly in terms of spirometric and Rmin,rs values (Tables 1 and 2). In this regard, it should be noted that the values of FEV1 (<80% of predicted) for patients in the COPD group (Table 2) allowed them to be classified as having moderate COPD (12). After tracheal intubation but before the commencement of maintenance anesthesia, Rmin,rs was not significantly different among the three subgroups treated with different anesthetics (Tables 1 and 2).
Control Group (FEV1/FVC >70%)
At 5 and 10 min of maintenance anesthesia, Rmin,rs had decreased significantly and to the same extent for the two volatile anesthetic subgroups (Table 3, Fig. 1), but not for the patients who had received thiopental. In one patient given isoflurane, resistance did not decrease.
|
|
Group with COPD (FEV1/FVC <70%)
At 5 min of maintenance anesthesia, Rmin,rs decreased significantly in the subgroup given sevoflurane, while this occurred at 10 min in the group receiving isoflurane (Table 3, Fig. 2). At 10 min, the percentage of Rmin,rs decrease was similar in the two subgroups (Fig. 2).
|
Approximately 90% of the total decrease in Rmin,rs from immediately after tracheal intubation to 10 min of 1.1 MAC of anesthesia was obtained by 5 min of sevoflurane, while this percentage was only approximately 54% for isoflurane administration.
Finally, a variable percentage of COPD patients did not respond to volatile anesthetics with a decrease in pulmonary resistance. This percentage, statistically larger compared with the control group (P = 0.013), was approximately 12% for sevoflurane and 18% for isoflurane and did not differ between volatile anesthetics (P = 0.58).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Our results are of clinical relevance because patients with COPD undergoing thoracic surgery are theoretically at the most risk of intraoperative bronchospasm, both because of their frequent smoking and because of the use of a DLT, which is probably more traumatic than a normal single-lumen endotracheal tube (5). Surprisingly, this was not the case when volatile anesthetics were used. The clinical implication of this finding could be seen in the ability of volatile anesthetics to reverse intraoperative bronchospasm. The latter can be responsible for pulmonary dynamic hyperinflation (DH) in the presence of expiratory V' limitation (EFL). Eltayara et al. (18) have previously demonstrated that patients with COPD with an FEV1 
60% of predicted, as in our study, could exhibit EFL in the supine position because of the reduction of functional residual capacity that also normally occurs during anesthesia. Because EFL implies concomitant DH, the latter can be responsible for deleterious effects on lung mechanics and hemodynamics (19). Even a small improvement in airway resistance caused by volatile anesthetic administration can decrease the extent of DH and reduce the intrathoracic pressure.
Although COPD did not alter responsiveness to either isoflurane or sevoflurane compared with patients with almost normal lung function (control group), not all patients with COPD responded to volatile anesthetics. The percentage of patients with COPD who did not respond varied from 18% to 12% for isoflurane and sevoflurane, respectively. The inability of this study to demonstrate a significant difference between isoflurane and sevoflurane in this respect may have been the result of the number of patients. In any case, this phenomenon was barely present in the control group and was not reported in patients with mild lung disease (1,20). This could be of clinical interest because it may imply that the more severe the lung disease, the smaller the number of patients in whom volatile anesthetics can reverse bronchospasm.
COPD seems responsible for another finding of our study, because sevoflurane acted faster than isoflurane only in patients with COPD. We are unable to explain the ability of sevoflurane to bronchodilate more rapidly than isoflurane in patients with COPD, although its lower solubility would theoretically permit faster tissue equilibration, thereby giving it an advantage over the other volatile anesthetics. We can speculate that the nonhomogeneous lung of patients with COPD, characterized by regional differences in mechanical properties and time constant inequalities, could delay the end-organ anesthetic concentration to a point at which the physical differences between the two volatile anesthetics could play a role. However, isoflurane can cause an unspecific airway irritation, which can enhance an initial difference between sevoflurane and isoflurane.
Although only sevoflurane significantly decreased Rmin,rs at 5 minutes of volatile anesthesia, this ability did not result in a larger reduction at 10 minutes compared with isoflurane (Table 3). This partially contradicts the data reported by Rooke et al. (1), who showed that sevoflurane decreased Rmin,rs more than isoflurane. However, a different effect from volatile anesthetic administration could have been expected in our study because it has been characterized by a patient population with more severe lung disease and by the use of a more traumatic DLT.
In conclusion, we have demonstrated that both sevoflurane and isoflurane can bronchodilate patients with COPD. Although the results are superimposed after 10 minutes of volatile anesthesia, sevoflurane acts faster than isoflurane. COPD does not alter the individual’s responsiveness to volatile anesthetics, but rather increases the possibility that patients will not respond to either sevoflurane or isoflurane.
|
Footnotes |
|---|
Presented at the 12th World Congress of Anesthesiologists, Montreal, Canada, June 2000.
Accepted for publication July 9, 2004.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  J.-I. Satoh, M. Yamakage, T. Kobayashi, N. Tohse, H. Watanabe, and A. Namiki Desflurane but not sevoflurane can increase lung resistance via tachykinin pathways Br. J. Anaesth., May 1, 2009; 102(5): 704 - 713. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
